MX2020008326A - Formas de co-cristales de un analogo de novobiocina y prolina. - Google Patents
Formas de co-cristales de un analogo de novobiocina y prolina.Info
- Publication number
- MX2020008326A MX2020008326A MX2020008326A MX2020008326A MX2020008326A MX 2020008326 A MX2020008326 A MX 2020008326A MX 2020008326 A MX2020008326 A MX 2020008326A MX 2020008326 A MX2020008326 A MX 2020008326A MX 2020008326 A MX2020008326 A MX 2020008326A
- Authority
- MX
- Mexico
- Prior art keywords
- proline
- crystal forms
- novobiocin
- analog
- dimethyltetra
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627570P | 2018-02-07 | 2018-02-07 | |
| PCT/US2019/016304 WO2019156907A1 (en) | 2018-02-07 | 2019-02-01 | Co-crystal forms of a novobiocin analog and proline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008326A true MX2020008326A (es) | 2020-09-28 |
Family
ID=65444361
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008326A MX2020008326A (es) | 2018-02-07 | 2019-02-01 | Formas de co-cristales de un analogo de novobiocina y prolina. |
| MX2022012856A MX2022012856A (es) | 2018-02-07 | 2020-08-06 | Formas de co-cristales de un analogo de novobiocina y prolina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012856A MX2022012856A (es) | 2018-02-07 | 2020-08-06 | Formas de co-cristales de un analogo de novobiocina y prolina. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10717755B2 (enExample) |
| EP (1) | EP3749675B1 (enExample) |
| JP (3) | JP2021512910A (enExample) |
| KR (2) | KR20240155354A (enExample) |
| CN (2) | CN112020506B (enExample) |
| AR (1) | AR114245A1 (enExample) |
| AU (3) | AU2019217821B2 (enExample) |
| BR (1) | BR112020016205A2 (enExample) |
| CA (2) | CA3226385A1 (enExample) |
| CL (2) | CL2020002051A1 (enExample) |
| CO (1) | CO2020009761A2 (enExample) |
| EA (1) | EA202091885A1 (enExample) |
| IL (2) | IL315865A (enExample) |
| MX (2) | MX2020008326A (enExample) |
| MY (1) | MY209803A (enExample) |
| PE (1) | PE20211446A1 (enExample) |
| SG (1) | SG11202007530XA (enExample) |
| TW (3) | TWI868593B (enExample) |
| WO (1) | WO2019156907A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021512910A (ja) * | 2018-02-07 | 2021-05-20 | リアタ ファーマシューティカルズ インコーポレイテッド | ノボビオシン類似体とプロリンとの共結晶形態 |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| CN115181146B (zh) * | 2021-04-02 | 2024-06-04 | 浙江普洛家园药业有限公司 | 一种新生霉素的提取工艺 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011306391B2 (en) * | 2010-09-23 | 2016-12-15 | Nuformix Limited | Aprepitant L-proline composition and cocrystal |
| TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| CN104159584A (zh) * | 2011-11-25 | 2014-11-19 | 诺弗米克斯有限公司 | 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体 |
| EP2602249B1 (en) * | 2011-12-06 | 2015-08-12 | F.I.S. Fabbrica Italiana Sintetici S.p.A. | Synthesis of rosuvastatin by means of co-crystals |
| NZ629778A (en) * | 2012-02-09 | 2016-03-31 | Univ Kansas | C-terminal hsp90 inhibitors |
| US9556216B2 (en) * | 2012-08-31 | 2017-01-31 | Novartis Ag | 2′-Ethynyl nucleoside derivatives for treatment of viral infections |
| TW201512201A (zh) * | 2013-03-14 | 2015-04-01 | Forum Pharmaceuticals Inc | 化合物的多晶型及鹽類 |
| CN106536498A (zh) | 2014-06-24 | 2017-03-22 | 堪萨斯大学 | 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺 |
| PL3202772T3 (pl) | 2014-09-30 | 2021-02-22 | Jiangsu Hengrui Medicine Co. Ltd. | Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2 |
| JP2021512910A (ja) | 2018-02-07 | 2021-05-20 | リアタ ファーマシューティカルズ インコーポレイテッド | ノボビオシン類似体とプロリンとの共結晶形態 |
-
2019
- 2019-02-01 JP JP2020542665A patent/JP2021512910A/ja active Pending
- 2019-02-01 TW TW112106332A patent/TWI868593B/zh active
- 2019-02-01 PE PE2020001199A patent/PE20211446A1/es unknown
- 2019-02-01 EP EP19705879.5A patent/EP3749675B1/en active Active
- 2019-02-01 SG SG11202007530XA patent/SG11202007530XA/en unknown
- 2019-02-01 BR BR112020016205-1A patent/BR112020016205A2/pt unknown
- 2019-02-01 EA EA202091885A patent/EA202091885A1/ru unknown
- 2019-02-01 CA CA3226385A patent/CA3226385A1/en active Pending
- 2019-02-01 MX MX2020008326A patent/MX2020008326A/es unknown
- 2019-02-01 CA CA3090646A patent/CA3090646C/en active Active
- 2019-02-01 CN CN201980011980.6A patent/CN112020506B/zh active Active
- 2019-02-01 MY MYPI2020004057A patent/MY209803A/en unknown
- 2019-02-01 KR KR1020247033920A patent/KR20240155354A/ko not_active Ceased
- 2019-02-01 IL IL315865A patent/IL315865A/en unknown
- 2019-02-01 CN CN202410935084.1A patent/CN118894894A/zh active Pending
- 2019-02-01 TW TW113147071A patent/TWI915111B/zh active
- 2019-02-01 IL IL276583A patent/IL276583B2/en unknown
- 2019-02-01 AU AU2019217821A patent/AU2019217821B2/en active Active
- 2019-02-01 KR KR1020207025571A patent/KR102718111B1/ko active Active
- 2019-02-01 TW TW108104336A patent/TWI797249B/zh active
- 2019-02-01 WO PCT/US2019/016304 patent/WO2019156907A1/en not_active Ceased
- 2019-02-01 US US16/265,256 patent/US10717755B2/en active Active
- 2019-02-05 AR ARP190100277A patent/AR114245A1/es unknown
-
2020
- 2020-06-05 US US16/894,461 patent/US11401294B2/en active Active
- 2020-08-06 MX MX2022012856A patent/MX2022012856A/es unknown
- 2020-08-06 CO CONC2020/0009761A patent/CO2020009761A2/es unknown
- 2020-08-07 CL CL2020002051A patent/CL2020002051A1/es unknown
-
2022
- 2022-12-05 AU AU2022283638A patent/AU2022283638B2/en active Active
- 2022-12-27 CL CL2022003784A patent/CL2022003784A1/es unknown
-
2023
- 2023-02-13 US US18/168,495 patent/US20240043465A1/en not_active Abandoned
- 2023-10-05 JP JP2023173340A patent/JP2024001167A/ja not_active Withdrawn
-
2024
- 2024-10-25 AU AU2024227646A patent/AU2024227646A1/en active Pending
-
2025
- 2025-10-23 JP JP2025178611A patent/JP2026012851A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ629778A (en) | C-terminal hsp90 inhibitors | |
| CL2022003784A1 (es) | Formas co-cristalinas de un análogo de novobiocina y prolina | |
| ECSP19053616A (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| CR20210381A (es) | MOLÉCULA DE UNIÓN AL ANTÍGENO MULTIESPECÍFICA QUE TIENE ACTIVIDAD DE SUSTITUCIÓN DE LA FUNCIÓN DE COFACTOR DEL FACTOR VIII DE COAGULACIÓN DE SANGRE (FVIII) Y FORMULACIÓN FARMACÉUTICA QUE CONTIENE TAL MOLÉCULA COMO INGREDIENTE (Divisional Exp. 2020-0158) | |
| JOP20210154B1 (ar) | مثبطات kif18a | |
| BR112021007902A2 (pt) | Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos | |
| EA202092086A1 (ru) | Ингибиторы аргиназы | |
| MX2022005256A (es) | Inhibidores de cd73. | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| CR20210442A (es) | ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y (Divisional Exp. 2020-0214) | |
| EA201990949A1 (ru) | Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицине | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| EP3986873C0 (en) | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | |
| EA202192008A1 (ru) | Lilrb3-связывающие молекулы и варианты их применения | |
| MA46778A1 (fr) | Composition intranasale comprenant de la bétahistine | |
| EP3903806A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES MEDIATED BY TRPV1 ACTIVITY | |
| FR3075012B1 (fr) | Procede de traitement cosmetique par plasma froid | |
| EP3991727A4 (en) | Composition for treating degenerative brain diseases, containing 2-pentylfuran as active ingredient | |
| EA202191758A1 (ru) | Пептиды для лечения и профилактики диабета и связанных с ним заболеваний | |
| EA201692185A1 (ru) | Пролекарство 1,1'-(1,6-диоксо-1,6-гександиил)бис-d-пролина | |
| CO2020001375A2 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico | |
| BR112017015474A2 (pt) | inibidores de bace1 | |
| MA39533A1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
| CL2011003165A1 (es) | Compuestos derivados de 1-(2-alquil-2,3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; composicion farmaceutica; y su uso para el tratamiento o la prevencion de trastornos melatoninergicos tales como depresion, estres, trastornos del sueño, insomnio, diabetes, enfermedad de parkinson, enfermedad de alzheimer entre otros. | |
| EA202192254A1 (ru) | Fcmr-связывающие молекулы и их применение |